[A15-58] Nivolumab - Addendum to Commission A15-32
Last updated 05.02.2016
Project no.:
A15-58
Commission:
Commission awarded on 22.12.2015 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-40 | Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A15-32 | Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |